# Efficacy and Safety of AJU-S56 5% in Dry Eye Syndrome Patients

> **NCT06291194** · PHASE3 · UNKNOWN · sponsor: **AJU Pharm Co., Ltd.** · enrollment: 396 (estimated)

## Conditions studied

- Dry Eye Syndromes

## Interventions

- **DRUG:** AJU-S56 5%
- **DRUG:** Placebo Group(Vehicle)

## Key facts

- **NCT ID:** NCT06291194
- **Lead sponsor:** AJU Pharm Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11-10
- **Primary completion:** 2024-05
- **Final completion:** 2024-05
- **Target enrollment:** 396 (ESTIMATED)
- **Last updated:** 2024-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06291194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06291194, "Efficacy and Safety of AJU-S56 5% in Dry Eye Syndrome Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06291194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*